P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy
Publication
, Conference
Gibson, CM; Arbetter, DF; Jain, P; Halaby, R; Chi, G; Nafee, T; Korjian, S; Daaboul, Y; Goldhaber, SZ; Hull, RD; Gold, A; Hernandez, AF ...
Published in: European Heart Journal
August 1, 2017
Duke Scholars
Published In
European Heart Journal
DOI
EISSN
1522-9645
ISSN
0195-668X
Publication Date
August 1, 2017
Volume
38
Issue
suppl_1
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gibson, C. M., Arbetter, D. F., Jain, P., Halaby, R., Chi, G., Nafee, T., … Harrington, R. A. (2017). P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy. In European Heart Journal (Vol. 38). Oxford University Press (OUP). https://doi.org/10.1093/eurheartj/ehx502.p1732
Gibson, C. M., D. F. Arbetter, P. Jain, R. Halaby, G. Chi, T. Nafee, S. Korjian, et al. “P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy.” In European Heart Journal, Vol. 38. Oxford University Press (OUP), 2017. https://doi.org/10.1093/eurheartj/ehx502.p1732.
Gibson CM, Arbetter DF, Jain P, Halaby R, Chi G, Nafee T, et al. P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy. In: European Heart Journal. Oxford University Press (OUP); 2017.
Gibson, C. M., et al. “P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy.” European Heart Journal, vol. 38, no. suppl_1, Oxford University Press (OUP), 2017. Crossref, doi:10.1093/eurheartj/ehx502.p1732.
Gibson CM, Arbetter DF, Jain P, Halaby R, Chi G, Nafee T, Korjian S, Daaboul Y, Goldhaber SZ, Hull RD, Gold A, Hernandez AF, Cohen AT, Harrington RA. P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy. European Heart Journal. Oxford University Press (OUP); 2017.
Published In
European Heart Journal
DOI
EISSN
1522-9645
ISSN
0195-668X
Publication Date
August 1, 2017
Volume
38
Issue
suppl_1
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology